Skip to main content
. 2020 Jul;9(7):4111–4120. doi: 10.21037/tcr-20-1451

Table 5. Clinical response according to LMR-week 6 for hepatic carcinoma patients.

Response Number (N=36, %) Low LMR-week 6 (N=21, 58.3%) High LMR-week 6 (N=15, 41.7%)
CR 1 (2.8) 0 (0.0) 1 (6.7)
PR 6 (16.7) 2 (9.5) 4 (26.7)
SD 9 (25.0) 6 (28.6) 3 (20.0)
PD 20 (55.5) 13 (61.9) 7 (46.6)

N, number; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; LMR-week 6, lymphocyte-to-monocyte ratio 6 weeks after the start of PD-1 inhibitors.